HPAPI (High Potency Active Pharmaceutical Ingredients) Global Market – Forecast To 2023

Publishing Date : November, 2017
Report Code : HCPH 0107
Price:
Single license $4,950
Site license $6,750
Global license $9,000


The drugs are classified as High Potent if its Occupational Exposure Limit (OELs) ≤ 10µg/m3. The HPAPI global market is progressively increasing in terms of revenue and the rise in demand for outsourcing these intermediates, manufacturing is driven by expansion of oncology sector, which is the fastest among overall pharmaceutical sector.

The global HPAPI market is poised to grow at a high single digit CAGR to reach $27,293.4 million by 2023. HPAPI market is mainly classified by customer base, by business type, by molecule type and Applications. The global HPAPI market is broadly classified as Innovative HPAPI and Generic HPAPI based on customer base. Based on business type, the market is classified into Captive HPAPI & Merchant HPAPI. HPAPI market is segmented on the basis of molecule type as Synthetic HPAPI and Biotech HPAPI. HPAPI market application segment is classified into Oncology, Cardiovascular, Central Nervous System, Hormonal, Glaucoma, Infectious, metabolic, Inflammation and other therapeutic applications.

Among Innovative & generic HPAPI, Innovative HPAPI occupies the major share during 2016 and generic HPAPIs expected to grow at a highest CAGR from 2016 to 2023. Among business type, Captive HPAPI occupies the major share during 2016 and Merchant HPAPI is expected to grow at a highest CAGR from 2016 to 2023. Among molecule type, Synthetic HPAPI occupied the major share during 2016 and is expected to grow at high single digit CAGR from 2016 to 2023 to reach $17,434.4 million by 2023. Among Application segment, Oncology commanded the larger revenue in 2016 and is expected to grow at highest CAGR from 2016 to 2023. 

Increasing incidence of chronic and age-related diseases, rapid growth in oncology market, growing demand for Antibody Drug Conjugates (ADC), technological advancements in HPAPI market, growing CMOs are some of the factors which are driving the market. Requirement of large investments, stringent safety and handling specifications associated with production of HPAPI, stringent regulations are the factors hindering the market.

North America accounted for the highest market share in 2016 and followed by Europe. However, Asian countries especially China and India are the fastest growing regions with its growing demand for HPAPIs. Asia-Pacific is projected to grow with a highest CAGR from 2016 to 2023.

Major players in HPAPI market include Alkermes PLC (Ireland), Cambrex Corporation (U.S.),Dishman group (India), Dr. Reddy’s Laboratories (India), Lonza Group (Switzerland), Novasep (U.S.), Patheon N.V.( Netherland)(ThermoFisher Scientific), Pfizer (U.S.), Merck KGaA (Germany) and Teva Pharmaceutical Industries (Israel).

The report provides an in-depth market analysis of the above mentioned segments across the following regions:

  • North America
  • Europe
  • Asia-Pacific 
  • Rest of the World
  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKE AWAYS
    • 2.2     REPORT DESCRIPTION
    • 2.3     MARKETS COVERED
    • 2.4     STAKEHOLDERS
    • 2.5     RESEARCH METHODOLOGY
      • 2.5.1     MARKET SIZE ESTIMATION
      • 2.5.2     MARKET BREAKDOWN AND DATA TRIANGULATION
      • 2.5.3     SECONDARY SOURCES
      • 2.5.4     PRIMARY SOURCES
      • 2.5.5     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.5.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.5.7     ASSUMPTIONS
      • 2.5.8     KEY CHARECTERISTICS OF HPAPI MANUFACTURING
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
      • 3.3.1     DRIVERS AND OPPORTUNITIES
        • 3.3.1.1     INCREASING INCIDENCE OF CHRONIC AND AGE RELATED DISEASES
        • 3.3.1.2     RAPID GROWTH IN ONCOLOGY MARKET
        • 3.3.1.3     GROWING DEMAND FOR ANTIBODY DRUG CONJUGATES (ADCS)
        • 3.3.1.4     TECHNOLOGICAL ADVANCEMENTS IN HPAPI MARKET
        • 3.3.1.5     GROWING CMOS (CONTRACT MANUFACTURING ORGANIZATIONS) MARKET
      • 3.3.2     RESTRAINTS AND THREATS
        • 3.3.2.1     REQUIREMENT OF LARGE INVESTMENT
        • 3.3.2.2     STRINGENT SAFETY AND HANDLING SPECIFICATIONS ASSOCIATED WITH THE PRODUCTION OF HPAPI
        • 3.3.2.3     STRINGENT REGULATIONS
        • 3.3.2.4     ALTERNATIVE THERAPIES TO CURE THE CANCER
    • 3.4     PORTER’S FIVE FORCE ANALYSIS
      • 3.4.1     THREAT OF NEW ENTRANTS
      • 3.4.2     THREAT OF SUBSTITUTES
      • 3.4.3     RIVALRY AMONG EXISTING COMPETITORS
      • 3.4.4     BARGAINING POWER OF BUYERS
      • 3.4.5     BARGAINING POWER OF SUPPLIERS
    • 3.5     REGULATORY AFFAIRS
      • 3.5.1     U.S.
      • 3.5.2     EUROPE
      • 3.5.3     ASIA PACIFIC
      • 3.5.4     REST OF THE WORLD
    • 3.6     MARKET SHARE ANALYSIS BY MAJOR PLAYERS
    • 3.7     SUPPLY CHAIN ANALYSIS
    • 3.8     SELECTED TOP SELLING HPAPI
    • 3.9     RECENT HPAPI INVESTMENTS
  • 4     HPAPI GLOBAL MARKET, BY CUSTOMER BASE
    • 4.1     INTRODUCTION
    • 4.2     INNOVATIVE HPAPI
    • 4.3     GENERIC HPAPI
  • 5     HPAPI GLOBAL MARKET, BY BUSINESS TYPE
    • 5.1     INTRODUCTION
    • 5.2     CAPTIVE HPAPAI
    • 5.3     MERCHANT HPAPI
  • 6     HPAPI GLOBAL MARKET, BY MOLECULE TYPE
    • 6.1     INTRODUCTION
    • 6.2     SYNTHETIC HPAPIS
    • 6.3     BIOTECH HPAPIS
  • 7     HPAPI GLOBAL MARKET, BY APPLICATIONS
    • 7.1     INTRODUCTION
    • 7.2     CENTRAL NERVOUS SYSTEM DISORDERS
    • 7.3     ONCOLOGY
    • 7.4     HORMONAL DISORDERS
    • 7.5     GLAUCOMA
    • 7.6     INFECTIOUS DISEASES
    • 7.7     METABOLIC DISORDERS
    • 7.8     CARDIOVASCULAR
    • 7.9     INFLAMMATION
    • 7.10     OTHER THERAPEUTIC APPLICATIONS
  • 8     REGIONAL MARKET ANALYSIS
    • 8.1     INTRODUCTION
    • 8.2     NORTH AMERICA
      • 8.2.1     U.S.
      • 8.2.2     OTHERS
    • 8.3     EUROPE
      • 8.3.1     SWITZERLAND
      • 8.3.2     GERMANY
      • 8.3.3     U.K.
      • 8.3.4     OTHERS
    • 8.4     ASIA PACIFIC
      • 8.4.1     INDIA
      • 8.4.2     CHINA
      • 8.4.3     JAPAN
      • 8.4.4     OTHERS
    • 8.5     REST OF THE WORLD (ROW)
      • 8.5.1     BRAZIL
      • 8.5.2     REST OF LATIN AMERICA
      • 8.5.3     MIDDLE EAST & OTHERS
  • 9     COMPETITIVE LANDSCAPE
    • 9.1     INTRODUCTION
  • 10     MAJOR COMPANIES
    • 10.1     ALKERMES PLC
      • 10.1.1     OVERVIEW
      • 10.1.2     FINANCIALS
      • 10.1.3     SERVICE PORTFOLIO
      • 10.1.4     KEY DEVELOPMENTS
      • 10.1.5     BUSINESS STRATEGY
      • 10.1.6     SWOT ANALYSIS
    • 10.2     CAMBREX CORPORATION
      • 10.2.1     OVERVIEW
      • 10.2.2     FINANCIALS
      • 10.2.3     SERVICE PORTFOILIO
      • 10.2.4     KEY DEVELOPMENTS
      • 10.2.5     BUSINESS STRATEGY
      • 10.2.6     SWOT ANALYSIS
    • 10.3     DISHMAN GROUP
      • 10.3.1     OVERVIEW
      • 10.3.2     FINANCIALS
      • 10.3.3     SERVICE PORTFOILIO
      • 10.3.4     KEY DEVELOPMENTS
      • 10.3.5     BUSINESS STRATEGY
      • 10.3.6     SWOT ANALYSIS
    • 10.4     DR. REDDY’S LABORATORIES
      • 10.4.1     OVERVIEW
      • 10.4.2     FINANCIALS
      • 10.4.3     SERVICE PORTFOLIO
      • 10.4.4     KEY DEVELOPMENTS
      • 10.4.5     BUSINESS STRATEGY
      • 10.4.6     SWOT ANALYSIS
    • 10.5     LONZA GROUP
      • 10.5.1     OVERVIEW
      • 10.5.2     FINANCIALS
      • 10.5.3     SERVICE PORTFOLIO
      • 10.5.4     KEY DEVELOPMENTS
      • 10.5.5     BUSINESS STRATEGY
      • 10.5.6     SWOT ANALYSIS
    • 10.6     NOVASEP
      • 10.6.1     OVERVIEW
      • 10.6.2     FINANCIALS
      • 10.6.3     SERVICE PORTFOLIO
      • 10.6.4     KEY DEVELOPMENTS
      • 10.6.5     BUSINESS STRATEGY
      • 10.6.6     SWOT ANALYSIS
    • 10.7     PATHEON N.V.(THERMOFISHER SCIENTIFIC)
      • 10.7.1     OVERVIEW
      • 10.7.2     FINANCIALS
      • 10.7.3     SERVICE PORTFOLIO
      • 10.7.4     KEY DEVELOPMENTS
      • 10.7.5     BUSINESS STARTEGY
      • 10.7.6     SWOT ANALYSIS
    • 10.8     PFIZER INC.
      • 10.8.1     OVERVIEW
      • 10.8.2     FINANCIALS
      • 10.8.3     PRODUCT PORTFOLIO
      • 10.8.4     SERVICE PORTFOLIO
      • 10.8.5     KEY DEVELOPMENTS
      • 10.8.6     BUSINESS STRATEGY
      • 10.8.7     SWOT ANALYSIS
    • 10.9     MERCK KGAA
      • 10.9.1     OVERVIEW
      • 10.9.2     FINANCIALS
      • 10.9.3     PRODUCT PORTFOLIO
      • 10.9.4     KEY DEVELOPMENTS
      • 10.9.5     BUSINESS STRATEGY
      • 10.9.6     SWOT ANALYSIS
    • 10.10     TEVA PHARMACEUTICAL INDUSTRIES
      • 10.10.1     OVERVIEW
      • 10.10.2     FINANCIALS
      • 10.10.3     SERVICE PORTFOLIO
      • 10.10.4     KEY DEVELOPMENTS
      • 10.10.5     BUSINESS STRATEGY
      • 10.10.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     HPAPI GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 2     HPAPI GLOBAL MARKET REVENUE, BY CUSTOMER BASE (2015-2023) ($MN)
      • TABLE 3     INNOVATIVE HPAPI GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 4     GENERIC HPAPI GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 5     HPAPI GLOBAL MARKET REVENUE, BY BUSINESS TYPE (2015-2023) ($MN)
      • TABLE 6     CAPTIVE HPAPI GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 7     MERCHANT HPAPI GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 8     HPAPI GLOBAL MARKET REVENUE, BY MOLECULE TYPE (2015-2023) ($MN)
      • TABLE 9     SYNTHETIC HPAPI GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 10     BIOTECH HPAPI GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 11     HPAPI GLOBAL MARKET REVENUE, BY APPLICATIONS, (2015-2023) ($MN)
      • TABLE 12     CENTRAL NERVOUS SYSTEMS HPAPI GLOBAL MARKET REVENUE, BY REGION, (2015-2023) ($MN)
      • TABLE 13     ONCOLOGY HPAPI GLOBAL MARKET REVENUE,BY REGION, (2015-2023) $MN)
      • TABLE 14     HORMONAL DISORDERS HPAPI GLOBAL MARKET REVENUE,BY REGION, (2015-2023) ($MN)
      • TABLE 15     GLAUCOMA HPAPI GLOBAL MARKET REVENUE,BY REGION, (2015-2023) ($MN)
      • TABLE 16     INFECTIOUS DISEASES HPAPI GLOBAL MARKET REVENUE,BY REGION, (2015-2023) ($MN)
      • TABLE 17     METABOLIC DISORDERS HPAPI GLOBAL MARKET REVENUE,BY REGION, (2015-2023) ($MN)
      • TABLE 18     CARDIOVASCULAR HPAPI GLOBAL MARKET REVENUE,BY REGION, (2015-2023) ($MN)
      • TABLE 19     INFLAMMATION HPAPI GLOBAL MARKET REVENUE,BY REGION, (2015-2023) ($MN)
      • TABLE 20     OTHER APPLICATIONS HPAPI GLOBAL MARKET REVENUE,BY REGION, (2015-2023) ($MN)
      • TABLE 21     NORTH AMERICAN HPAPI MARKET REVENUE, BY CUSTOMER BASE, (2015-2023) ($MN)
      • TABLE 22     NORTH AMERICAN HPAPI MARKET REVENUE, BY BUSINESS TYPE, (2015-2023) ($MN)
      • TABLE 23     NORTH AMERICAN HPAPI MARKET REVENUE,BY MOLECULE TYPE, (2015-2023) ($MN)
      • TABLE 24     NORTH AMERICAN HPAPI MARKET REVENUE,BY APPLICATIONS , (2015-2023) ($MN)
      • TABLE 25     EUROPEAN HPAPI MARKET REVENUE, BY CUSTOMER BASE, (2015-2023) ($MN)
      • TABLE 26     EUROPEAN HPAPI MARKET REVENUE, BY BUSINESS TYPE, (2015-2023) ($MN)
      • TABLE 27     EUROPEAN HPAPI MARKET REVENUE,BY MOLECULE TYPE, (2015-2023) ($MN)
      • TABLE 28     EUROPEAN HPAPI MARKET REVENUE,BY APPLICATIONS, (2015-2023) ($MN)
      • TABLE 29     ASIA PACIFIC HPAPI MARKET REVENUE, BY CUSTOMER BASE, (2015-2023) ($MN)
      • TABLE 30     ASIA PACIFIC HPAPI MARKET REVENUE, BY BUSINESS TYPE, (2015-2023) ($MN)
      • TABLE 31     ASIA PACIFIC HPAPI MARKET REVENUE,BY MOLECULE TYPE, (2015-2023) ($MN)
      • TABLE 32     ASIA PACIFIC HPAPI MARKET REVENUE,BY APPLICATIONS, (2015-2023) ($MN)
      • TABLE 33     ROW HPAPI MARKET REVENUE, BY CUSTOMER BASE, (2015-2023) ($MN)
      • TABLE 34     ROW HPAPI MARKET REVENUE, BY BUSINESS TYPE, (2015-2023) ($MN)
      • TABLE 35     ROW HPAPI MARKET REVENUE,BY MOLECULE TYPE, (2015-2023) ($MN)
      • TABLE 36     ROW HPAPI MARKET REVENUE,BY APPLICATIONS (2015-2023) ($MN)
      • TABLE 37     EXPANSIONS, AGREEMENTS, ACQUISTIONS, APPROVALSAND OTHER DEVELOPMENTS (2015-2017)
      • TABLE 38     ALKERMES PLC: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN)
      • TABLE 39     ALKERMES PLC: TOTAL REVENUE, BY SEGMENTS, (2015-2017) ($MN)
      • TABLE 40     ALKERMES PLC: TOTAL REVENUE, BY SUB-SEGMENTS, (2015-2017) ($MN)
      • TABLE 41     ALKERMES PLC: TOTAL REVENUE, BY GEOGRAPHY, (2015-2017) ($MN)
      • TABLE 42     CAMBREX CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN)
      • TABLE 43     CAMBREX CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2015-2017) ($MN)
      • TABLE 44     DISHMAN GROUP: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 45     DISHMAN GROUP: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 46     DR. REDDY’S LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 47     DR. REDDY’S LABORATORIES: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 48     DR. REDDY’S LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 49     LONZA GROUP: TOTAL REVENUE AND R&D EXPENSES (2015-2017) ($MN)
      • TABLE 50     LONZA GROUP: TOTAL REVENUE, BY SEGMENT, (2015-2017) ($MN)
      • TABLE 51     LONZA GROUP: TOTAL REVENUE, BY GEOGRAPHY (2015-2017) ($MN)
      • TABLE 52     PATHEON N.V.: TOTAL REVENUE AND R&D EXPENSES (2015-2017) ($MN)
      • TABLE 53     PATHEON N.V.: TOTAL REVENUE, BY SEGMENT, (2015-2017) ($MN)
      • TABLE 54     PATHEON N.V.: TOTAL REVENUE, BY GEOGRAPHY (2015-2017) ($MN)
      • TABLE 55     PFIZER INC: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN)
      • TABLE 56     PFIZER INC: TOTAL REVENUE, BY SEGMENTS, (2015-2017) ($MN)
      • TABLE 57     PFIZER INC: TOTAL REVENUE, BY GEOGRAPHY, (2015-2017) ($MN)
      • TABLE 58     MERCK KGAA: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN)
      • TABLE 59     MERCK KGAA: TOTAL REVENUE, BY SEGMENTS, (2015-2017) ($MN)
      • TABLE 60     MERCK KGAA: TOTAL REVENUE, BY GEOGRAPHY, (2015-2017) ($MN)
      • TABLE 61     TEVA PHARMACEUTICAL INDUSTRIES: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN)
      • TABLE 62     TEVA PHARMACEUTICAL INDUSTRIES: TOTAL REVENUE, BY SEGMENTS, (2015-2017) ($MN)
      • TABLE 63     TEVA PHARMACEUTICAL INDUSTRIES: TOTAL REVENUE, BY GEOGRAPHY, (2015-2017) ($MN)

      LIST OF FIGURES

      • FIGURE 1     HPAPI GLOBAL MARKET SHARE AND REVENUE, BY REGION (2015-2023)
      • FIGURE 2     RESEARCH METHODOLOGY: HPAPI GLOBAL MARKET
      • FIGURE 3     HPAPI GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     HPAPI GLOBAL MARKET: FORECASTING MODEL
      • FIGURE 5     HPAPI GLOBAL MARKET: MARKET BREAKDOWN & DATA TRIANGULATION
      • FIGURE 6     HPAPI GLOBAL MARKET SEGMENTATION
      • FIGURE 7     MARKET DYNAMICS
      • FIGURE 8     HPAPI GLOBAL MARKET: PORTER’S ANALYSIS
      • FIGURE 9     HPAPI GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS 2016 (%)
      • FIGURE 10     HPAPI MARKET: SUPPLY CHAIN ANALYSIS
      • FIGURE 11     HPAPI GLOBAL MARKET SHARE, BY CUSTOMER BASE (2016 V/S 2023) (%)
      • FIGURE 12     HPAPI GLOBAL MARKET REVENUE, BY BUSINESS TYPE (2016 V/S 2023) ($ MN)
      • FIGURE 13     HPAPI GLOBAL MARKET REVENUE, BY MOLECULE TYPE (2016 V/S 2023) ($ MN)
      • FIGURE 14     HPAPI GLOBAL MARKET SHARE, BY APPLICATIONS (2016) (%)
      • FIGURE 15     HPAPI GLOBAL MARKET SHARE AND REVENUE, BY REGION (2016-2023) ($MN)
      • FIGURE 16     NORTH AMERICAN HPAPI MARKET REVENUE, BY CUSTOMER BASE, BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) ($MN)
      • FIGURE 17     NORTH AMERICAN HPAPI MARKET SHARE, BY APPLICATIONS (2016 V/S 2023) (%)
      • FIGURE 18     UNITED STATES HPAPI MARKET REVENUE, BY CUSTOMER BASE, BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) ($MN)
      • FIGURE 19     UNITED STATES HPAPI MARKET SHARE, BY APPLICATIONS (2016 V/S 2023) (%)
      • FIGURE 20     OTHER NORTH AMERICAN REGIONS HPAPI MARKET REVENUE, BY CUSTOMER BASE, BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) ($MN)
      • FIGURE 21     OTHER NORTH AMERICAN REGIONS HPAPI MARKET SHARE, BY APPLICATIONS (2016 V/S 2023) (%)
      • FIGURE 22     EUROPEAN HPAPI MARKET REVENUE, BY CUSTOMER BASE, BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) ($MN)
      • FIGURE 23     EUROPEAN HPAPI MARKET SHARE, BY APPLICATIONS (2016 V/S 2023) ($MN)
      • FIGURE 24     SWITZERLAND HPAPI MARKET REVENUE, BY CUSTOMER BASE, BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) ($MN)
      • FIGURE 25     SWITZERLAND HPAPI MARKET SHARE, BY APPLICATIONS (2016 V/S 2023) (%)
      • FIGURE 26     GERMANY HPAPI MARKET REVENUE, BY CUSTOMER BASE,BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) ($MN)
      • FIGURE 27     GERMANY HPAPI MARKET SHARE, BY APPLICATIONS (2016 V/S 2023) (%)
      • FIGURE 28      U.K. HPAPI MARKET REVENUE, BY CUSTOMER BASE, BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) ($MN)
      • FIGURE 29     U.K. HPAPI MARKET SHARE, BY APPLICATIONS (2016 V/S 2023) (%)
      • FIGURE 30     OTHER EUROPEAN REGIONS HPAPI MARKET REVENUE, BY CUSTOMER BASE, BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) ($MN)
      • FIGURE 31     OTHER EUROPEAN REGIONS HPAPI MARKET SHARE, BY APPLICATIONS (2016 V/S 2023) (%)
      • FIGURE 32     ASIA PACIFIC HPAPI MARKET REVENUE, BY CUSTOMER BASE, BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) ($MN)
      • FIGURE 33     ASIA PACIFIC HPAPI MARKET SHARE,BY APPLICATIONS (2016 V/S 2023) (%)
      • FIGURE 34     INDIA HPAPI MARKET REVENUE, BY CUSTOMER BASE,BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) ($MN)
      • FIGURE 35     INDIA HPAPI MARKET SHARE, BY APPLICATIONS (2016 V/S 2023) (%)
      • FIGURE 36     CHINA HPAPI MARKET REVENUE, BY CUSTOMER BASE,BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) ($MN)
      • FIGURE 37     CHINA HPAPI MARKET SHARE, BY APPLICATIONS (2016 V/S 2023) (%)
      • FIGURE 38     JAPAN HPAPI MARKET REVENUE, BY CUSTOMER BASE,BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) ($MN)
      • FIGURE 39     JAPAN HPAPI MARKET SHARE, BY APPLICATIONS (2016 V/S 2023) (%)
      • FIGURE 40     OTHER ASIA PACIFIC REGIONS HPAPI MARKET REVENUE, BY CUSTOMER BASE, BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) (%)
      • FIGURE 41     OTHER ASIA PACIFIC REGIONS HPAPI SHARE, BY APPLICATIONS (2016 V/S 2023) (%)
      • FIGURE 42     ROW HPAPI MARKET REVENUE, BY CUSTOMER BASE,BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) ($MN)
      • FIGURE 43     ROW HPAPI MARKET SHARE BY APPLICATIONS (2016 V/S 2023) (%)
      • FIGURE 44     BRAZIL HPAPI MARKET REVENUE, BY CUSTOMER BASE, BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) ($MN)
      • FIGURE 45     BRAZIL HPAPI MARKET SHARE, BY APPLICATIONS (2016 V/S 2023) (%)
      • FIGURE 46     REST OF LATIN AMERICA HPAPI MARKET REVENUE, BY CUSTOMER BASE, BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) ($MN)
      • FIGURE 47     REST OF LATIN AMERICA HPAPI MARKET REVENUE, BY APPLICATIONS (2016 V/S 2023) (%)
      • FIGURE 48     MIDDLE EAST & OTHERS HPAPI MARKET REVENUE, BY CUSTOMER BASE, BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) ($MN)
      • FIGURE 49     MIDDLE EAST & OTHERS HPAPI MARKET SHARE, BY APPLICATIONS (2016 V/S 2023) (%)
      • FIGURE 50     KEY GROWTH STRATEGIES, (2015 – 2017)
      • FIGURE 51     SWOT: ALKERMES PLC
      • FIGURE 52     SWOT: CAMBREX CORPORATION
      • FIGURE 53     SWOT: DISHMAN GROUP
      • FIGURE 54     SWOT: DR. REDDY’S LABORATORIES
      • FIGURE 55     SWOT: LONZA GROUP
      • FIGURE 56     SWOT: NOVASEP
      • FIGURE 57     SWOT: PATHEON N.V.
      • FIGURE 58     SWOT: PFIZER INC.
      • FIGURE 59     SWOT: MERCK KGAA
      • FIGURE 60     SWOT: TEVA PHARMACEUTICAL INDUSTRIES

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     AENOVA GROUP GMBH
      • 2     ALKERMES PLC
      • 3     ALMAC GROUP
      • 4     ABBOTT LABORATORIES
      • 5     ABBVIE CONTRACT MANUFACTURING
      • 6     ADC BIOTECHNOLOGY
      • 7     ADC THERAPEUTICS
      • 8     AGNO PHARMA
      • 9     AJINOMOTO (ALTHEA INC.)
      • 10     ALCAMI CORPORATION
      • 11     AMPAC FINE CHEMICALS
      • 12     AMRI GLOBAL
      • 13     ANVI PHARMA
      • 14     ASTRAZENECA(SPIROGEN)
      • 15     ASYMCHEM LABORATORIES
      • 16     AVANTHERA S.A.
      • 17     AVARA PHARMACEUTICAL SERVICES
      • 18     AXCELLERATE PHARMA SERVICES
      • 19     BACHEM
      • 20     BAXTER INTERNATIONAL
      • 21     BAYER
      • 22     BIOCON LIMITED
      • 23     BIOPHARMA TECHNOLOGY
      • 24     BIOPHORE INDIA PHARMACEUTICALS PVT. LTD
      • 25     BIOVECTRA
      • 26     BIOTECHNIQUE
      • 27     BOEHRINGER INGELHEIM
      • 28     BRISTOL-MYERS SQUIBB
      • 29     BRYLLAN LLC
      • 30     BUCHIGLAS-USA CORP.
      • 31     CAMBREX CORPORATION
      • 32     CATALENT PHARMA SOLUTIONS INC
      • 33     CELGENE BIOTECHNOLOGY
      • 34     CERBIOS PHARMA SA
      • 35     CHEMCON
      • 36     CHEMIGRAN PTE LTD.
      • 37     CIPLA
      • 38     CONSORT MEDICAL
      • 39     CUSTOM PROCESSING SERVICES INC
      • 40     DALTON PHARMA SERVICES
      • 41     DEC-USA INC.
      • 42     DISHMAN GROUP
      • 43     DOTTIKON EXCLUSIVE SYNTHESIS
      • 44     DR. REDDY'S LABORATORIES
      • 45     EMCURE PHARMACEUTICALS
      • 46     ESTEVE QUIMICA
      • 47     EUROFINS SCIENTIFIC
      • 48     EUTICALS
      • 49     EVONIK INDUSTRIES
      • 50     EVOTEC A.G.
      • 51     FAREVA
      • 52     FARHISPANIA GROUP
      • 53     FERMION
      • 54     FERRO CORPORATION
      • 55     FORMOSA LABORATORIES INC.
      • 56     FRESENIUS KABI
      • 57     GRANUELS
      • 58     GP PHARM
      • 59     HELSIN ADVANCED SYNTHESIS.
      • 60     HERAEUS
      • 61     HIKAL LIMITED
      • 62     HIKMA PHARMACEUTICALS
      • 63     HOVIONE
      • 64     ICROM S.P.A
      • 65     IDIFARMA PHARMACEUTICAL DEVELOPMENT S.L.
      • 66     INTAS BIOPHARMACEUTICALS
      • 67     INTERNATIONAL CHEMICAL INVESTORS S. E
      • 68     JOHNSON MATTHEY
      • 69     KYONGBO PHARMACEUTICAL CO. LTD
      • 70     LAURUS SYNTHESIS INC
      • 71     LIPOCINE
      • 72     LONZA GROUP
      • 73     LUPIN LIMITED
      • 74     MAYNE PHARMA (LIBERTAS PHARMA INC)
      • 75     MEDICHEM
      • 76     MERCK KGAA
      • 77     MERSANA THERAPEUTICS INC.
      • 78     MINAKEM HIGH POTENT
      • 79     MITSUBISHI TANABE PHARMA CORP.
      • 80     NATCO PHARMA
      • 81     NEULAND HEALTH SCIENCES PRIVATE LIMITED
      • 82     NOVARTIS
      • 83     NOVASEP HOLDING SAS
      • 84     OLON S.P.A.
      • 85     OPKO HEALTH
      • 86     OSO BIOPHARMACEUTICALS MANUFACTURING LLC
      • 87     PCAS
      • 88     PFANSTIEHL
      • 89     PFIZER
      • 90     PIERRE FABRE
      • 91     PIRAMAL PHARMA SOLUTION
      • 92     POWDER SYSTEMS LIMITED
      • 93     PROCOS S.P.A
      • 94     PROJECT PHARMACEUTICS
      • 95     QS PHARMA LLC
      • 96     REGIS TECHNOLOGIES INC.
      • 97     R-PHARM GERMANY GMBH.
      • 98     SCINOPHARM TAIWAN LIMITED
      • 99     SEATTLE GENETICS INC.
      • 100     SEIGRIED HOLDING
      • 101     SERVIER CDMO
      • 102     SHILPA MEDICARE
      • 103     STASON PHARMACEUTICALS
      • 104     STRIDES ARCOLABS
      • 105     SUNDIA MEDITECH
      • 106     SYMBIOSIS PHARMACEUTICAL SERVICES
      • 107     SYNTAGON AB
      • 108     SYNTHON BIOPHARMACEUTICALS
      • 109     TEVA PHARMACEUTICAL INDUSTRIES
      • 110     THERMOFISHER SCIENTIFIC (PATHEON N.V.)
      • 111     UMAN PHARMA
      • 112     UMICORE N.V.
      • 113     VION PHARMACEUTICALS, INC
      • 114     VXP PHARMA SERVICES
      • 115     WUXI PHARMATEC
      • 116     YPROTECH LIMITED